ReviewFrontiers in pharmacology2022
The Role of Imaging Biomarkers to Guide Pharmacological Interventions Targeting Tumor Hypoxia.
Review in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 30 citations in OpenAlex.
- Whole-Body Oxygen-Enhanced MRI of Tumor-Bearing Mice Under Hyperbaric Oxygenation.Magnetic resonance in medicine · 2026Article
- Combining Oxygen-Enhanced MRI and Electron Paramagnetic Resonance Oximetry for Quantitative OE-MRI (qOE-MRI) as a Method for Mapping Absolute Oxygen Levels (pOMagnetic resonance in medicine · 2026Article
- Enhanced Sonodynamic Therapy and Radiotherapy Efficacy: Modified Polyethylene Glycol-Bismuth Trioxide Nanoplatform for Targeted Tumor Treatment.Biomaterials research · 2026Article
- Quantification of Oxygenation and Oxygen Consumption Rates in the Mouse Brain Based on Tissue Oxygen Level-Dependent (TOLD) MRI.NMR in biomedicine · 2025Article
- From Hypoxia to Bone: Reprogramming the Prostate Cancer Metastatic Cascade.International journal of molecular sciences · 2025Review
- The neglected burden of chronic hypoxia on the resistance of glioblastoma multiforme to first-line therapies.BMC biology · 2024Review
- Celebration of 80 years of EPR.Applied magnetic resonance · 2024Article
- Pulse and CW EPR Oximetry Using Oxychip in Gemcitabine-Treated Murine Pancreatic Tumors.Molecular imaging and biology · 2024Article
- Sensitive simultaneous measurements of oxygenation and extracellular pH by EPR using a stable monophosphonated trityl radical and lithium phthalocyanine.Free radical biology & medicine · 2024Article
- The combined treatment with ketogenic diet and metformin slows tumor growth in two mouse models of triple negative breast cancer.Translational medicine communications · 2024Article
- The Combined Treatment with Ketogenic Diet and Metformin Slows Tumor Growth in Two Mouse Models of Triple Negative Breast Cancer.Research square · 2023Article
- Mapping the topography of spatial gene expression with interpretable deep learning.bioRxiv : the preprint server for biology · 2023Article
- Murine Breast Cancer Radiosensitization Using Oxygen Microbubbles and Metformin: Vessels Are the Key.International journal of molecular sciences · 2023Article
- Research Progress on Stimulus-Responsive Polymer Nanocarriers for Cancer Treatment.Pharmaceutics · 2023Review
- Review
- Review
- Absolute oxygen-guided radiation therapy improves tumor control in three preclinical tumor models.Frontiers in medicine · 2023Article
- EPR Investigations to Study the Impact of Mito-Metformin on the Mitochondrial Function of Prostate Cancer Cells.Molecules (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypoxia is a common feature of solid tumors that contributes to angiogenesis, invasiveness, metastasis, altered metabolism and genomic instability. As hypoxia is a major actor in tumor progression and resistance to radiotherapy, chemotherapy and immunotherapy, multiple approaches have emerged to target tumor hypoxia. It includes among others pharmacological interventions designed to alleviate tumor hypoxia at the time of radiation therapy, prodrugs that are selectively activated in hypoxic cells or inhibitors of molecular targets involved in hypoxic cell survival (i.e., hypoxia inducible factors HIFs, PI3K/AKT/mTOR pathway, unfolded protein response). While numerous strategies were successful in pre-clinical models, their translation in the clinical practice has been disappointing so far. This therapeutic failure often results from the absence of appropriate stratification of patients that could benefit from targeted interventions. Companion diagnostics may help at different levels of the research and development, and in matching a patient to a specific intervention targeting hypoxia. In this review, we discuss the relative merits of the existing hypoxia biomarkers, their current status and the challenges for their future validation as companion diagnostics adapted to the nature of the intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.